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The response of human peripheral blood lymphocytes (HPBL) 
was characterized using: the cytokinesis-blocked 
micronucleus (CBMN) assay, premature chromosome 
condensation (PCC) assay, FITC-Annexin V labeling 
procedure, chip-based DNA ladder assay, and the comet 
assay. The samples of whole blood or isolated lymphocytes 
collected from 10 different healthy donors were irradiated in 
vitro with 60 MeV protons or 250 kV X-rays, in the dose range 
of 0.3 Gy – 4.0 Gy. The HPBL were located in Eppendorf 
vessels located in especially prepared PMMA (Poly(methyl 
methacrylate)) phantom and irradiated with protons in the 
fully modulated Spread Out Bragg Peak (SOBP) mode. 
Dosimetry was performed in accordance to the 
recommendations of the IAEA TRS-398 protocol. 
Peripheral blood lymphocytes showed decreased ability to 
proliferate after irradiation that reduced with increasing 
radiation doses of either radiation types as evident by the 
reduced nuclear division index seen in the cytokinesis-block 
micronucleus (CBMN) assay. Proton irradiation resulted in a 
relatively higher incidence of cell death compared to those 
irradiated with X-rays. Cell death was due to both apoptosis 
and necrosis. Chip-based DNA ladder assay showed different 
degrees of fragmentation of the genomic DNA after proton 
irradiation indicating peripheral blood lymphocytes, which 
are prone to undergo an apoptotic mode of cell death, 
predominantly undergo a necrotic mode of cell death after 
proton irradiation. Differences in DNA damages following 
irradiation with protons and X-rays were apparent also at the 
intracellular distribution of cytogenetic damages as 
visualized by the PCC and CBMN assays. Alkaline comet assay 
showed a linear dose-response relationship for the DNA 
damage immediately after irradiation. Dose response 
relationship for the DNA damage indicated higher efficiency 
of protons in inducing DNA strand breaks presented as the 
ratio of the two α coefficients (1.37).   
Our results, contribute to a better understanding of the 
differences in the response of human peripheral blood 
lymphocytes to proton and X-ray irradiation. These studies 
may eventually help determine the suitability of patients 
with cancer for treatment with a given radiation type based 
on their normal tissue response and ability to predict 
treatment related adverse effects.    
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In the clinical practice of proton therapy, the biologic 
effectiveness of protons relative to photons (i.e., the 
"relative biologic effectiveness" or RBE) has simplistically 
been assumed to have a generic fixed value of 1.1.  This 
value is based on an average of results of numerous in-vitro 
and in-vivo experiments conducted under limited conditions – 
most commonly, at high doses per fraction (e.g., 6–8 Gy) and 
in the middle of the spread-out Bragg peak where the RBE is 
relatively constant and close to the average value of 1.1.  
Furthermore, the RBE data have been acquired for only a 
limited number of cell lines, tissues, and endpoints.  To 
justify the assumption of RBE of 1.1, it is argued that, 
clinically, no adverse responses have been reported with its 
use.  However, large uncertainties in the treatment 
processes may have obscured the variability of the RBE. 
In reality, the RBE is a function of multiple variables 
including dose per fraction, linear energy transfer (LET), cell 
and tissue type, endpoint, etc. It has been shown to vary 
from values lower than 1.1, perhaps lower than even 1, to as 
much as 4.  Emerging clinical evidence, still somewhat 
anecdotal, is showing that neglecting RBE variability may 
lead to unforeseen toxicities and recurrences.  However, 
establishing an unequivocal connection between unforeseen 
events and the use of RBE of 1.1 is challenging since there 
are numerous confounding factors.   These include 
uncertainty in the particle therapy dose actually delivered 
and patient-specific factors. 
As a consequence, there is a continuing debate about the 
validity of the assumption of RBE=1.1.  At the same time, 
efforts to obtain more precise and accurate RBE information 
are accelerating.  High-precision in-vitro and in-vivo 
experiments are being designed and conducted to obtain the 
large amounts of data required.  Attempts are also being 
made to extract clinically-relevant RBE from treatment 
response data, particularly from PET and MR image 
biomarkers.  Such RBE data need to be incorporated into 
predictive models of RBE, which can be used to explain 
treatment response more reliably and to design treatment 
plans.  The improved knowledge of variable RBE is expected 
to not only help explain unforeseen events but, more 
importantly, to lead to improvements in treatment planning, 
which in turn may enhance the effectiveness of proton 
therapy.  This could, for instance, be achieved by 
incorporating variable RBE in the optimization of IMPT in such 
a way as to confine high RBE protons to within the target 
volume and away from critical normal tissues. 
This presentation will focus on proton therapy.  For particles 
heavier than protons, the RBE is generally not assumed to 
have a fixed generic value.  Nevertheless, considerable 
uncertainties exist in RBE for all particles, which can have a 
significant impact on outcomes.  
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Most of adult stem cells are maintained in a quiescent state 
considered as a survival mechanism responding to DNA 
damages induced by ionizing radiation. Stem cells then are 
able to rapidly proliferate and are essential for restoration of 
tissue function. In the brain, Neural Stem Cells (NSCs) are 
known to be responsible for adult neurogenesis participating 
to cognition and Whole Brain Radiotherapy (WBRT) induces 
memory loss due to impaired neurogenesis. Here we 
compared the effect of FLASH versus conventional-RT on 
NSCs after WBRT and especially investigated quiescence and 
neurogenesis potential.  
WBRT at FLASH and conventional dose rate was performed 
using LINAC prototypes. Mice received single doses RT at 
50GyFLASH (>50Gy/s), 10GyCONV (0.04Gy/s) and sham-RT. 
Two months post-IR, before the sacrifice, cognitive tests 
were performed to evaluate memorization impairments. Two 
hours before the sacrifice animals received BrdU injection. 
Brains were collected for immunohistochemical analysis of 
NSCs quiescence using FoxO3-Sox2 (Renault et al. 2009). 
We showed that 50GyFLASH-RT does not induce any 
macroscopic toxicity whereas 10GyCONV is the maximum 
tolerated dose (Acharya et al. 2009). We observed a 
memorization loss after 10GyCONV-RT whereas cognition is 
not affected at 50GyFLASH two months post-IR. At the same 
time point, SGZ BrdU+ clusters are maintained at doses up to 
20GyFLASH whereas 10GyCONV totally impairs the 
